28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
03 Feb
FING-B
OK Moderator - jeg bliver bare så vred, når vi, der abbonnerer på EI - gang på gang bliver provokere..
32
05 Feb
OMXC20
  Inden jeg starter med at forklare, hvad det er der aktuelt sker på aktiemarkedet, vil jeg henvise ..
26
01 Feb
FING-B
Jeg forstår ikke, hvorfor myndighederne ser den anden vej, når hedgefonde helt åbenlyst forsøger at ..
24
05 Feb
 
    En lærerinde i 3. klasse stillede sine elever det evigt relevante spørgsmål:"Hvad vil du gerne..
23
02 Feb
I:SP500
Så er vi der igen - volatilitet som dybest set kun gavner de spekulanter i markedet, som reelt intet..
17
31 Jan
EXQ
Hvad angår prostatakræft, som jeg fik konstateret for 1½ år siden, og som jeg er i behandling for - ..
17
05 Feb
FING-B
Vi 8 har snakket med flere analysefirmaer i dag som jeg ikke lige kan huske navnene på, og de fortæl..
14
05 Feb
NOVO-B
Købte NN i kurs 247,60 i 2014. Solgte i december 2015 i kurs 293,20. Købte Danske Bank i januar i ku..
12
03 Feb
FING-B
Citat af TOP10 ovenfor: " Det gode ved en fingerprint scanner, hvis man vil stjæle oplysninger, er a..
12
01 Feb
25NYK01EA47
Ville blot lige markere, at jeg stædigt holder fast i, at de store indeks stadig ikke har brudt mods..
11

Novae Group plc : Notice of Results

05/02/2016 15:47:43
5 February 2016                                                                                     For immediate release Novae Group plc NOTICE ..

Form 8.3 - Sainsbury (J) plc

05/02/2016 12:11:02
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Alliance Trust PLC : Transaction in Own Shares 5 February 2016 correction

05/02/2016 09:55:55
5 February 2016 Alliance Trust PLC TRANSACTION IN OWN SHARES (Correction) The announcement released this morning was incorrectly headed Net asset Value A..

Most read news

  • 24 hours
  • 48 hours
  • 1 week

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
07 February 2016 12:40:26
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160125.1 - EUROWEB2 - 2016-02-07 13:40:26 - 2016-02-07 12:40:26 - 1000 - Website: OKAY